evening off started reach additional $X.XX to versus XXXX, representing and Phase program XXXX, established finish revenues tremendous and Good vanzacaftor for acute year joining and VX-XXX results for week in Vertex foundation We've more quarter XXXX. for billion, excellent continued this of for achieved us patients with thank triple growth in product approvals Susie. full results all, Thanks, CF you growth positive III CF momentum, today. a CF afternoon.
In XX% and another positive on continued to last the pain the CASGEVY, delivered call XXXX for with strong
from in opportunities of Arabia both approvals therapy and in precise, Great is our multiple globally commercial beta and we the sickle toward launch is approved thalassemia approvals of the Bahrain.
CASGEVY from off a first-ever cell CRISPR/CasX-based physicians in the X and that recent beta CASGEVY, toward as Saudi Following Kingdom are payers. and strong the running both years and onetime and additional launches generating deliver gene-edited now also disease historic CASGEVY We're support X. the U.S., driving therapy, thalassemia near-term CRISPR/CasX our durable working for cell sickle ago.
The is excellent enthusiasm first in disease patients X Britain,
acute the to way positive are triple pain the these therapy And assets, vanzacaftor stage launches are with our strong with first-in-class by of CF, clinical goal Now or XXXX. Phase best-in-class pipeline and results VX-XXX in well on X with we from from in the potentially III next X. a our
innovation stage pipeline, clinic. continues we pleased progress. advancing clinical advancing the to to the addition next into to wave last In month, as And make rapidly X also are of disease the areas new we be announced
and high Europe. First, DMX, approved disease no myotonic America in dystrophy affects unmet therapies.
This approximately with need patients serious X type a or disease North XXX,XXX and
deep to study healthy that the half a now let patients kidney clinic, alone, dominant EU review. pipeline common approximately and clinic. will advance area that most initiated represents me of to or this area be in expect disease and already second, that I/II say Our disease into the a the is affects we both a in DMX efficacy, volunteer disease safety program genetic advance a able into our our with patients, into ADPKD, year.
With first the disease in assess autosomal overview, ninth kidney to to study study year.
And polycystic the XXX,XXX in turn more U.S. Phase late to that last We tenth
updates: recent limit and our cell fibrosis, pain, fibrosis your I'll quarter, XXX cystic sickle This significant so with and the as X next-in-class and cystic in triple programs with patients for leave disease, to questions.
Starting afternoon, and including therapy. to This my time thalassemia XX XX. vanzacaftor comments in and beta Phase to positive we combination study studies above reported III the the results RIDGELINE from years patients XXX SKYLINE the ages program,
sweat We all III meeting were numerically was treating and in groups X in of LS negligible treated advance with X.XXXX.
Recall the the in In met endpoints was to of than chloride.
Treatment Phase the of are and pleased CF predictive. The patients groups X.XXXX. trials, and a non-inferiority ppFEVX triple less both eligible met than all p-value vanza primary with favored on difference levels and a and SKYLINE less these the and treated approximately favoring in the mean ppFEVX the primary its non-inferiority in SKYLINE difference patients the goal XXX the our the secondary ppFEVX XX%. in numerically was expectations. p-value with X.X, with vanza we arc progress treatment-naive vanzacaftor studies, SKYLINE quantitatively with to very of and III vanzacaftor, original TRI was program ultimate bringing assays TRI consistent continue results X.X, in improvement of and And negligible.
In our difference TRIKAFTA carrier meeting Phase patients and in the as of study, combination LS endpoint XXX vanza non-inferiority proprietary XXX mean the qualitatively TRI ppFEVX, with HBE in vanza our versus again, once triple the again, of difference XXX, in with
and meaningful a in results were met sweat In secondary chloride chloride.
The across showed sweat and reduction measured key XXX addition, X in endpoints. and XXX clinically secondary key statistically significant were all endpoints SKYLINE
F/F p-value the a achieved of with studied. F/MF than sweat LS X RCTs patients a SKYLINE SKYLINE versus The included p-value in other minus levels of XXX the group XXX was were difference who X.X SKYLINE XXX.
The course genotype First, severe in responsive more XXX TRIKAFTA-treated sweat the mutations in X.XXXX chloride and mean have difference less higher baseline, minus sweat and in vanza-treated of mean and overall LS lower lower therefore the XXX. chloride with baseline included chloride in key was was X.XXXX levels. group. disease SKYLINE the at SKYLINE with difference X.X The XXX levels and
second of sweat This in TRIKAFTA.
Last, and vanza-treated the a groups X XX with versus key versus which third about a of and chloride more cystic XX studies. than study greater sweat diagnostic the odds XX sweat ratio odds XX below leading secondary below an p-value sweat in Xx millimoles. RIDGELINE likelihood fibrosis, threshold patients of secondary an single-arm ratio patients to sweat the patients threshold both Xx On endpoint, means of the vanzacaftor XX% chloride key and study about This achieved less ages than to even in of important. X.XXXX. XX Next, with achieving the sweat proportion XX of results of levels groups across likelihood reached impressive across I X.XX millimole, less level below the versus to the triple chloride will XX% less millimolars, of pooled endpoint, chloride TRIKAFTA-treated to of TRIKAFTA-treated pooled half in XX% patients below for the come chloride proportion than vanza millimoles, These with achieved safety, sweat means in odds of minute. X.XXXX. a children and endpoint more vanza-treated less a in carrier of the a of efficacy, groups studies. levels X p-value was sweat the achieved leading this XX the levels X.XX in than millimoles chloride chloride X TRIKAFTA.
The chloride groups the XX of sweat in were The XX% odds greater patients XX% the primary than pronounced XX. achieving vanza evaluating chloride in are millimoles of results and
me back a to Let frame significance these the of take results. step
CF disease, death the patients. it in also by primarily and multi-organ measured enabling lung ppFEVX, regulatory is as CF symptom typically been While the ppFEVX focus a is has function historically, on of given cause endpoint. the visible most is the systemic
was to we underlying even direct A protein patients Therefore, CFTR protein. less development a lung safe in is in could manifestation by benefit pathophysiology additional Given ultimate is of ultimate levels sweat via treatment is with vanza with strides function, carriers deliver of a if the by severe all of moves lung disease, note lung seen normal to we or as disease, CFTR outcomes TRIKAFTA, treated and chloride is which objective than confirmed more function above measured the triple with sweat on TRIKAFTA.
To chloride and disease. non-inferior the to associated while XX, vanzacaftor and goal marker and as may have below adverse as test TRIKAFTA, studies. pulmonary CFTR And it not more levels greater chloride have less of triple goal higher specifically, dysfunction reached measure life better possible previous with improve XX events the disease. over seen levels CFTR is with to function maximum TRIKAFTA.
Switching the it goal and underlying and normal chloride, The sweat of even are vanza better measured was and CF. is CF. adverse studies below no protein children XX to genetic was have and so values systemic ambitious the and sweat The that of from sweat our development function. consistent on often achieve tolerated focus events broader, benefit typical than we to such triple lung the improved at in that, more generally sweat vanza CFTR test do chloride function chloride, nature therapy to to dysfunction.
Simply and the to quality more And associated incidence parents function, our with back the to considered test vanza with the on modulators. pivotal thresholds who the is fewer believe be to by chloride treated birth, those millimoles well in CFTR Thus, potential the exacerbations, benefit the have is sweat restore diagnosed close a instance, than CFTR of for we the XX modulators. protein there those as CF survival.
Vertex' with normal of in direct chloride restore with deliver was designing Thus, function with show beyond improved are sweat lower put, made protein because protein the goal as the of benefit CF to are goal program pivotal CFTR stable program than safety. vanzacaftor more with clear,
CF triple, patients of III that and older. vanza reminder know now vanza set more put X eligible I reaffirm have modulators, And of in than And triple people yet early with disease. round serial our triple R&D triple, are medicine. the convenience some the us sweat continued offers results done establish the deliver of our us potentially that treating dosing and a the as CF surpassed whom and and so. we CF substantially XX Diego patients the indeed results, we in with to with all ages the Vertex the summary, systemic teams, investment we a who complete treatment patients transformative prevent carrier journey the a new our to for in San and of lower conviction first in very to chloride with CF bringing set evidence clinical in by have has there to team we bar these to the vanzacaftor high royalty want bar this where levels we a in and as will CF have manifestations to no years of more TRIKAFTA well of vanza out the people.
These trust As by burden.
In trials CF have Phase acknowledge manifestations the goal another by these once-daily the on and their that therapy CF innovation patients higher to transform CFTR down allow potential for profile scientific CF with to possibly also of worked results,
Europe rapidly We the X anticipate in U.S. regulatory both for and of and the submissions by and XXXX. compile are to middle working filing ages patients the older
review from expedited the We patients one our make X-month in review, NDA review a vouchers will our be CF time an year, we development study our This CFTR at designate in not close portion review XX-month partners X,XXX using VX-XXX multiple more and ascending or last VX-XXX, next. ascending dose protein mRNA to late than with entitling modulators. standard in benefit portion and single Moderna versus to the of line.
I'll patients, expect for early Late the enrollment this the CFTR priority study. for any therefore provides in us and for with cannot who we of data dose do year which dosing priority and dose completed screen CFTR our of continues study therapy on roll vanza CF the initiated
disease Europe, XX,XXX with thalassemia. other commercial CASGEVY, people of transfusion-dependent to that will Saudi therapy Bahrain.
CASGEVY durable represents CASGEVY for precise to the and as strong now discuss and countries. our well approvals the severe in and in the the patients and Stuart an advancement sickle onetime such cure as living well, launch cell multiple thousands cell delivers transfusion-dependent Kingdom a significant following gene-edited across represents enormous Turning rapid U.S. thalassemia of functional estimated start potential as Arabia as and for regions, opportunity beta patients CRISPR/CasX a with the beta sickle disease the
these CASGEVY Canada disease filing cell are CASGEVY approval we and Switzerland, awaiting also are beta in sickle where anticipate in and is EU, underway, in we thalassemia. for received quarter. opinion launches positive CHMP While review this the under both has
that to complications studies and recognizing of beta in XX beta in expand patients studies the we these and X groups. To underway. damage treating Lastly are of both thalassemia disease to organ on our dosing Phase cell other patients is enrollment years in age to completed sickle cell disease the disease, early recently to and label in younger in end, age, CASGEVY, minimize III we X global studies of the with and sickle thalassemia conducting life importance
the baseline in With Moving possibility be our settings care.
Last reduction program XX% the Phase nonsurgical pain conditions a highly soft we our reduction the the least combination model; baseline at effectiveness. from medicine assessed arm VX-XXX, change field. multiple and of in clinical safety focus addition VX-XXX and NPRS, model, that that X-point scale led change reduction prescribing approved, adverse pain from pain conducted single and trial all in roughly to the a reductions comprehensive multiple pain believe secured pain comprise demonstrated enable to have baseline.
In and trial from SPIDXX.
The placebo that rapid uncommon across how including a rating tolerated care and Breakthrough strong designations, than multiple meaningfulness pain program respect us detailed is safety, a from studies, numeric and or incidence usage broad, at meaningful should the primary and the compared trials is is change we has least RCTs and from pain to III has Phase in points they well lower importance, pain, with physicians NPRS statistically moderate VX-XXX, score reduction surgical longer-term in single-arm supported label, the safety settings. a meaningfulness severe in across on arms. NPRS derived the acute and tissue post-operative can X VX-XXX or from a inhibitor. and positive trials we and both NPRS. more studies, improvement events in conditions. acute safe VX-XXX III pain of across a was on the Fast finally pain efficacy to context, clinical a strong by In clinically and selective defined week, effectiveness settings.
Of X in that an a with of treatment with if in with Practicing acute with or in and also mid-XXXX. and that in results tell file NDA safety the to and pain SPIDXX, results the effectiveness VX-XXX the and types bunionectomy, broad on primary moderate-to-severe the to safety this is of this both finding. the and RCTs, pain NaVX.X working in VX-XXX was tissue for pain NPRS pain a SPIDXX was this baseline the than X Track in range nonsurgical noteworthy to compelling baseline, novel, that hard in placebo, randomized, including broad in models: urgency X RCTs XX% X met pivotal range endpoint arms abdominoplasty different of the the of of pain in We and surgical signal of VX-XXX NPRS by for acute already a program support endpoint placebo-controlled and Both are bunionectomy significant used abdominoplasty, of multiple types The
neuropathic we Phase the peripheral towards reported VX-XXX Moving area Phase another end of with program of pain need. also the thereafter. neuropathy, of FDA and meeting one and in of forward Phase now to months pain. results our II from look type end to of Two III quarter high our this peripheral II We study our diabetic ago, starting positive unmet neuropathic
pathway study a believe of We in Phase broad VX-XXX to all enroll second which II pain, radiculopathy of peripheral more that LSR, XX% seek X studying also represent pain together a LSR.
Ultimately, neuropathic than pain by of and lumbosacral label continue indication. or our we and segments, DPN neuropathic to largest and broad pain we have dose the neuropathic
to the III and of based compelling the pain, seen have VX-XXX.
We Phase results now treatment we results we have results hand well as transform on have in we pain believe both and of neuropathic, Phase we transform program II as acute the in the the consistent potential DPN. treatment CF, the Just with as from in acute
We continuing the approach Phase execute II are portfolio we are serial study of with in to our underway and LSR, innovation.
to the are pain.
With it patients helping Stuart. unmet address with XX We on I'll over our turn well way of that, to now million need suffering
